Common shares, no par value
- Symbol
- FENC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Fennec Pharmaceuticals Inc.
Other Events
Item 8.01. Other Events On May 21, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSIÒ.
Current securities
Registered securities in this filing
FENNEC PHARMACEUTICALS INC. · 8-K · Filed 2026-05-22
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events
On May 21, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 fencf-20260521xex99d1.htm EX-99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES NEW RESEARCH supporting INTEGRATION AND use of pedmark® at the 2026 ASCO Annual Meeting ~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity ~ Research Triangle Park, NC, May 21, 2026 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program. These four independently led studies build upon the established safety and efficacy of PEDMARK® - currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors, and recognized by the National Compre…
Open exhibit ↗